北美新型药物输送系统市场-增长、趋势和预测(2022 - 2027 年)

北美新型药物递送系统市场按给药途径、NDDS 模式(靶向药物递送系统、受控药物递送系统、调制药物递送系统)和地理区域划分。

市场快照

CAGR
Study Period: 2017-2025
Base Year: 2021
CAGR: 5.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

市场增长的主要因素包括对药物控释的日益增长的需求,以及促进 NDDS 发展的技术进步。大多数药物都有一个最佳浓度范围和药物在体内控释的要求。高于或低于规定范围的浓度可能有毒或不会产生治疗益处。透皮贴剂、鼻腔系统、微胶囊等是在控释系统下考虑的一些常见系统。因此,药物控释的需求推动了新型药物输送系统市场的发展。递送系统的稳定性是影响药物递送系统市场的最重要因素之一。限制因素包括严格的监管指南和产品召回。

报告范围

根据本报告的范围,新型药物输送系统 (NDDS) 旨在提高药物的疗效。NDDSs用于提高药物的生物利用度,减少不良反应和副作用,增加药物稳定性。市场按管理途径、NDDS 模式和地理位置进行细分。

By Route of Administration
Oral Drug Delivery Systems
Injectable Drug Delivery Systems
Pulmonary Drug Delivery Systems
Transdermal Drug Delivery Systems
Others
By Mode of NDDS
Targeted Drug Delivery Systems
Controlled Drug Delivery Systems
Modulated Drug Delivery Systems
Geography
North America
United States
Canada
Mexico

Report scope can be customized per your requirements. Click here.

主要市场趋势

口服给药系统预计在预测期内增长最快

由于患者依从性高、成本效益高、无菌限制最小、剂型设计的灵活性和易于生产,口服给药已被发现是最优选和最方便的给药途径。在口服给药时,药物应在不稳定的生物环境下得到保护,包括胃肠道诱导的药物降解和口服给药后到达靶位之前的首过肝脏效应。口服给药的主要驱动力是慢性病发病率的增加、使用先进的口服给药系统对药物进行重新配制和重新定位,以及大型制药公司对内部口服给药技术开发能力的巨额投资。根据 Globocan 的数据,2018 年共有 2,129 个,

North America cancer cases.webp

竞争格局

市场参与者正专注于开发创新的治疗方案,以抢占最大的市场份额。一些市场参与者是雅培实验室、阿斯利康公司、拜耳公司、F. Hoffmann-La Roche 公司、葛兰素史克公司、强生公司、默克公司、诺华公司、辉瑞公司和赛诺菲公司

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Need of Controlled Release of Drugs

      2. 4.2.2 Technological Advancements Promoting Development of NDDS

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Guidelines and Product Recalls

      2. 4.3.2 Stability Issues of the Devices

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Oral Drug Delivery Systems

      2. 5.1.2 Injectable Drug Delivery Systems

      3. 5.1.3 Pulmonary Drug Delivery Systems

      4. 5.1.4 Transdermal Drug Delivery Systems

      5. 5.1.5 Others

    2. 5.2 By Mode of NDDS

      1. 5.2.1 Targeted Drug Delivery Systems

      2. 5.2.2 Controlled Drug Delivery Systems

      3. 5.2.3 Modulated Drug Delivery Systems

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 AstraZeneca PLC

      3. 6.1.3 Bayer Healthcare Pharmaceuticals

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Novartis AG

      7. 6.1.7 Merck & Co.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Roche Holding AG

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Novel Drug Delivery Systems (NDDS) Market market is studied from 2017 - 2025.

The North America Novel Drug Delivery Systems (NDDS) Market is growing at a CAGR of 5.8% over the next 5 years.

Abbott Laboratories, Roche Holding AG, Merck & Co., GlaxoSmithKline PLC, Bayer AG are the major companies operating in North America Novel Drug Delivery Systems (NDDS) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!